Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER review management

Executive Summary

Drug center Director Janet Woodcock, MD, takes on additional role as acting director of CDER's Office of Review Management following the resignation of Murray Lumpkin, MD. Lumpkin will remain at FDA "on detail to a deputy center director position for the next several weeks to assist me in the ORM transition," Woodcock told CDER staff in an Oct. 13 memo. During that time, Lumpkin will evaluate "various options outside the center." His resignation was for personal reasons, according to the memo. During his tenure as the ORM head, Lumpkin contributed to the creation and ongoing implementation of the OTC labeling reg
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS008576

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel